Neu oncogene

Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer prognostic factor, predictive factor, and target for therapy. Oncologist 1998 3 237-252. 

Disis, M. L., Grabstein, K. H., Sleath, R. R., and Cheever, M. A. 1999. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5 1289-1297. 

Ross, J. S., Sheehan, C. E., and Fletcher, J. A. 2001. HER-2/neu oncogene amplification determined by fluorescence in situ hybridization. In Molecular Pathology Protocols (A. A. Killeen, ed.), pp. 93-104. Humana Press, Totowa, NJ. 

Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. 1987. Human breast cancer Correlation of relapse and survival with amplification of the FlER-2/neu oncogene. Science 235, 177-182. 

Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115. 

Bouchard, L., Lamarre, L., Tremblay, P. J., and Jolicoeur, P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell51, 931-936. 

Myers, J. N., Drebin, J. A., Wada, T., and Greene, M. I. (1991). Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, pl85neu. MethodsEnzymol. 198, 277-290. 

L. (1987). Human breast cancer Correlation of relapse and survival with amplification of IIER2/neu oncogene. Science 235, 177-182. 

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenicinsitu hybridization apractical alternative forfluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 157(5) 1467-72. 

Bargmann, G. I., Hung, M. C., and Weinberg, R. A. (1986a). Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pl85. Cell 45, 649-657. 

Neu. The neu oncogene was found in a rat neuroblastoma. The neu-protooncogene encodes a EGF-like receptor with tyrosinekinase activity. The Neu receptor binds EGF and a specific Neu-activating factor. Neu may play a role in neurogenesis. 

Tandon AK, QarkGM, Chamness GC, et al. Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989 7 1120. 

Zhai YF, Beittenmiller H, Wang B et al (1993) Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 53 2272-2278... 

Yu, D., Matin, A., Xia, W., Sorgi, F., Huang, L., and Hung, M. C. (1995) Liposome-mediated in vivo gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11(7), 1383-1388. 

Results of proliferating nuclear antigen immunohis-tochemical studies indicate that the myoepithelial cell, rather than the epithelial cell, is the predominant proliferating element in EMC. There is no overexpression of FlER-2/neu oncogene and, from initial studies, determination of DNA ploidy offers no additional prognostic information. 

Yamanaka Y, Eriess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993 24 1127-1134. 

---